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Abstract
Thymoma is a disease with malignant potential, which has a recurrence rate after complete resection ranging from
5 to 50 %. Multiple studies on the risk factors, treatment or prognosis have been reported. Many of them are
controversial, however. In this review, we summarized some accepted risk factors, means of diagnosis and different
treatments of recurrent thymoma. The risk factors of recurrent thymoma haven’t been well-studied, and its
management remains controversial. We reviewed the literatures and found some key points which should be
noticed during the surgery of initial thymoma. Although reoperation should be taken into account preferentially,
multimodal treatments are also available. The prognosis are also been discussed.
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Background
Thymoma is a disease with malignant potential, which
shows a possibility of recurrence after complete resec-
tion. The International Thymic Malignancy Interest
Group (ITMIG) has recently defined a standard set of
definitions for recurrence [1]: (1) the term ‘recurrence’ is
appropriate if all disease has been potentially eradicated
(R0 resection); (2) recurrences are classified as local
(anterior mediastinum), regional (intrathoracic not con-
tiguous with the thymus), and distant (intrapulmonary
and extrathoracic); and (3) the freedom-from- recur-
rence outcome indicator should be used for any study
on recurrence after R0 resection, and 5- and 10-year
outcomes should be reported in every series.
The recurrence of thymoma is rare, the rate ranges
according to different reports. In the research of Japa-
nese Association for Research on Thymus (JART),
among all the 2835 thymoma patients received operation
during 1991–2010, 420 (14.8 %) experienced recurrence
[2]. The average disease-free time of recurrent patients
was 5 years, and recurrence occurred 32 years after
initial operation was also reported [3]. The time to
relapse was 10 years for patient of clinical stage I, and
3 years for patient of stage II, III and IV.
Most recurrence are local and regional [4, 5]. 46–80 %
of recurrent cases are found in the thoracic cavity [5–7],
and then in the mediastinum and lungs [2, 8], distant
metastases occur in less than 5 % of the cases [9]. In the
report of Detterbeck et al. [10], Among patients with
recurrences, the pleural space or the lung was involved
in 58 % (most often as a nodule under the parietal
pleura), the pericardium or mediastinum in 41 %, bone
in 10 %, and liver in 8 %.
According to the study of The Japanese Association
for Chest Surgery [11], of 862 patients who had informa-
tion, 67 (7.8 %) developed recurrence. The recurrence
rates in stages I, II, III, and IV were 0.9, 4.1, 28.4, and
34.3 %, respectively; In thymic carcinoma, 51 % of pa-
tients developed recurrence, whereas, in thymic carcin-
oid, 64 % of patients had recurrence.
* Correspondence: zhao_hg75@hotmail.com; zxm_zj@sina.com
1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou
310022, People’s Republic of China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Luo et al. Journal of Cardiothoracic Surgery  (2016) 11:140 
DOI 10.1186/s13019-016-0533-9
The risk factors of recurrent thymoma
Masaoka classification
The Masaoka classification was one of the well-accepted
risk factors of thymoma recurrent. Tumors capsulated
and not infiltrated with neighbor tissue or organs recur
very rarely (0 to 5 %) [12]; invasive tumors show a recur-
rence rate ranging from 20 to 50 % from stage 1 to stage
4a, respectively [11, 13]. Most stage I and II thymomas
recur locally or regionally [14]. The majority of the re-
current patients had advanced disease of stage III or IV
(n = 329; 81.2 %) [2]. Some researchers believe that the
invasion of major blood vessel (stage IIIb) strongly sug-
gest tumor recurrence [15]. The more advance Masaoka
stage is, the more possible remote recurrence happens.
World Health Organization histology
The recurrence of thymoma is closely related to its
World Health Organization (WHO) histology. It is re-
ported that few patients of type A/AB thymoma experi-
ence recurrence, when the recurrent rate was 28.6 % and
over 50 % for patients with type B and type C thymoma,
respectively [11]. The recurrence of type C thymoma is
quicker and more frequent than the other types; its me-
tastasis is also much common [16, 17]. Wright et al. [7]
raised a point of view that if divide thymoma among
four groups (A/AB, B1/B2, B3 and C) according to
WHO histology, its rate of local invasion and recurrence
rises one by one. The recurrent rate of type C thymoma
is several times higher than the others (41 % vs 9.7 %)
[17]. There is some relationship between the WHO hist-
ology and Masaoka classification of thymoma, as most
type A and type B thymoma are at stage I and stage II,
and type B2/B3/C thymoma are usually at stage III and
stage IV [8].
Other risk factors
Incomplete initial resection is regarded as one of the risk
factors of recurrence. Taken the possibility of ectopic
and vagus thymus into consideration, a synchronous
tumor resection and clean-up of the fat tissue in anterior
mediastinum is helpful to avoid the recurrence of thym-
oma, in spite of the tumor’s volume and the integrity of
its envelope [18, 19]. The method of initial operation
may also be a risk factor. Some researchers raised con-
cern about whether minimally invasive (Video assisted
thoracic surgery or Da Vinci robot) methods is prone to
induce recurrence [20, 21], but recent reports indicated
that there isn’t significant difference between minimally
invasive surgery and traditional open operation for expe-
rienced surgeons [22, 23]. In case of thymomas greater
than 2 cm and without fat tissue surrounding the thymic
capsule, the manipulation of the tumor may cause seed-
ing of tumor cells that are responsible for local and
pleural recurrences [16]. Recurrence may occur within
the thymus left in place during the first surgical proced-
ure or in the thoracic compartment where thymoma was
located, in the pleural space opened to allow complete
resection, and even at the site of the wound of the first
operation or the mediastinal biopsy initially performed
for tissue diagnosis [24], which suggests the risk of
implantation metastasis during the operation. Other
researchers find that tumor larger than 8 cm is also a
risk factor of recurrence [7, 25]. Otherwise, studies on
the molecular biology discover that DNA aneuploidy,
IFN-αand IL-12 are also helpful in predicting the recur-
rence of thymoma [26–28].
The diagnosis of recurrent thymoma
Symptoms
The recurrence of thymoma is usually insidious, most
patients have no complains [29]. Myasthenia gravis is
most common among all the symptoms, which may
appear on more than half of the patients [17, 30]. One
patient who shows the symptom of myasthenia gravis
induced by the initial thymoma, may be also caught by it
when tumor recurrent [31]. In addition, some patients
could have oppress symptoms such as chest pain and
dyspnea, which are like initial thymoma.
Computerized tomographic scanning
Computerized tomographic scanning (CT) is the routine
examination for patients after initial tumor resection,
and is also the main way to screen recurrence thymoma.
A research shows that 94 % of asymptomatic patients
found the mass by CT [32]. If myasthenia gravis or other
symptoms arises, CT could be the first choice. However,
CT is a morphological examination; and local tissue
adhesion, fibrillation and scarring induced by surgery or
post-surgery radiotherapy may harass the interpretation
of CT images.
Positron emission tomography
Positron emission tomography (PET-CT) could make up
the shortness of CT by measuring the metabolic rate of
tissue, which improve the accuracy of diagnosis. CT
overall sensitivity for detecting the mediastinal recur-
rence and pleural dissemination of thymomas is 71 %,
and its specificity is 85 %; as for PET/CT, the overall
sensitivity and specificity for thymoma recurrence are 82
and 95 %, respectively [33]. When employed for the
diagnosis of thymoma recurrence in the anterior medias-
tinum, the sensitivity of PET-CT has reached 100 %,
when CT is only 55 % [33]. Besides that, the metabolic
rate of tissue showed by PET-CT is related to the grade
of malignancy of recurrent thymoma [34]. PET-CT may
even help to classify the World Health Organization
histology of recurrent thymoma [35]. Nevertheless, the
recurrence thymoma on the pleura usually appears as
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multiple nodules in the image of PET-CT, and the calcu-
lation of metabolic rate is difficult because of partial vol-
ume effect [36].
Others
Magnetic resonance imaging (MRI) is a means with low ra-
diation dose, and is better at representing cystic tissue than
CT; MRI also has an advantage in differentiating thymic
hyperplasia and thymoma, even evaluating whether the
phrenicus nerve is infiltrated [37]. Literature states that
ECT shows increased uptake of Tc-99 m in the primary
and recurrent thymoma [38], which indicates ECT may be
useful in the diagnosis.
Pathology
Pathology is the gold standard of tumor diagnosis, which
consists cytopathology and histopathology. As in most
cases, the tumor locates in the anterior mediastinal,
sheltered by sternum and surrounded by main vessels,
so the puncture guided by CT or ultrasound could be
performed only if the tumor spreads out of the sternum.
Histopathology could be performed through mediastino-
scope, thoracoscope or open surgery.
The prevent of recurrent thymoma
In the operation
The principle of tumor-free is crucial for the prevention
of local and regional prevention. Complete resection of
the entire thymus is recommended, along with extreme
care during dissection and en bloc resection of the sur-
rounding structures infiltrated by the tumor [8]. Block-
ade of the tumor surface could reduce the risk of tumor
implantation metastasis.
Most recurrence are found pleural recurrence, it is not
clear whether they are related to the particular biology of
the tumor or whether they are consequences of seeding of
the tumor, possibly determined by disruption of the cap-
sule during the operation. For this reason, some surgeons
recommend to avoid opening the mediastinal pleura and
avoid miniinvasive procedures with a transpleural ap-
proach (thoracotomy, VATS, or robot assisted) [14, 15].
Postoperative
As quite a bit of recurrent thymoma are in the mediasti-
num, so there are viewpoints that mediastinal radiation
after initial operation are effective in reducing the recur-
rent rate [6]. However, subsequent reports showed that
adjuvant radiotherapy was associated with late morbidity
to the heart, lungs, and other mediastinal structures
[39–41]; the cost of radiation therapy is sometimes
higher than surgery, and mediastinal radiation does not
prevent pleural implants, which represents the most
common pattern of recurrence [8], so selective use of ra-
diation therapy was suggested.
Currently, adjuvant radiotherapy is not indicated for
stage I thymoma, as it’s easy to achieve R0 resection,
and histology is usually type A or B1 [11, 42, 43], the re-
currence rate is almost 0 [42, 44]. Adjuvant radiotherapy
does not add any advantage for stage II thymoma which
is completely resected; and it might be indicated for type
B2/B3 lesions [45, 46]. Thus, adjuvant radiotherapy
should be reserved in case of close proximity of the
tumor to the resection margins or extracapsular involve-
ment of the mediastinal fat or presence of adhesions to
the pericardium and mediastinal pleura [8]. Multiple re-
searches show adjuvant radiotherapy makes no benefit
for stage III thymoma [11, 42, 47]. Adjuvant radiother-
apy should be considered for patients receiving incom-
plete resection or with suspected involvement of the
surgical margins, or with type B2/B3 histology or in case
of previous open biopsy that could contribute to con-
taminate the surgical wound [8]. Besides, some authors
suggest a potential role for postoperative chemotherapy,
as most recurrence of stage III thymoma are within the
pleura [47]. Stage IV patients generally received adjuvant
mediastinal radiation therapy, which cannot prevent
pleural or pulmonary metastases but may prevent medi-
astinal recurrence [5]. Surgical removal followed by
intrapleural hyperthermic chemotherapy is another
treatment strategy [48].
Follow-up
Patients with incomplete resections and patients with
thymic carcinoma are recommended for more frequent
(computed tomographic surveillance every 6 months)
follow-up during the first 3 years given their higher pro-
pensity for relapse [49]. An annual chest CT within
5 years after thymoma resection and biannual chest CTs
after 5 years for at least 20 years are recommended [32].
The treatment of recurrent thymoma
Once the thymoma is relapse, the effect of treatment
may not be ideal. As the initial operation usually resect
all the thymus and fat tissue in the mediastinum, expose
vessels and nerves, so the re-operation is quite risky and
difficult. Reducing-tumor operation plus hyperthermia
perfusion chemotherapy may be a good choice [50].
Recurrent thymoma is malignant, and multimodal
treatment is necessary. Thymoma is a slow glowing
tumor, patient may get a long survival without any treat-
ment. Supportive treatment may be the best choice for
those who have a low PS score and couldn’t tolerant fur-
ther treatment.
Surgery
Most doctors regard surgery as the first choice for pa-
tients of recurrent thymoma. The average rates of 5- and
10-year overall survival after recurrence in patients
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treated surgically were 70.9–82.7 % and 49.6–68.2 %,
and in patients treated nonsurgically, they were 29.6–
43.5 % and 18.4–25.4 %, respectively [3, 4, 51]. The
patients of recurrent thymoma who receive operation
have an obvious better overall survival rate than those
treated with chemotherapy only [5, 12, 52–55]. Some
researchers raised an issue that the operation should be
performed as long as the tumor is resectable and the
patient could sustain the surgery [29]. Other opinions
propose that surgical resection should be considered in
patients with a localized recurrence after apparently
successful initial therapy; in some patients with stage IV
disease, the resection of isolated pleural metastases is an
appropriate initial approach; for cases with multiple
pleural metastases, chemotherapy, with or without sub-
sequent surgery, is often appropriate [56]. The operative
mortality was reported ranging from 0 to 13.3 %, and
the operative morbidity ranging from 0 to 32.1 %; most
patients suffering from operative mortality and morbid-
ity had myasthenia gravis [57]. So it seems necessary to
control myasthenia gravis with drugs pre-operative.
For patients with single pleural recurrences, a partial re-
section is necessary [16]. Sometimes pleural recurrences
are extensive, with huge pleural implants infiltrating the
lung and the diaphragm; in such cases, an extended pleur-
opneumonectomy may be the only chance to attempt radi-
cality [58]. Strict selection criteria for such an aggressive
treatment include young age, excellent cardiopulmonary
function, and absence of metastatic disease using PET-CT
[8]. The type of surgical approach depends upon the site
and side of the recurrence, the associated surgical risks for
bone infection, and the surgeon’s preference. Pleural recur-
rences are approached best by means of thoracotomy,
although recent reports indicate that sternotomy may be
performed; mediastinal recurrence usually is approached by
means of median sternotomy. The combination of median
sternotomy and anterior thoracotomy may improve expos-
ure of the mediastinum and the ipsilateral hemithorax [8].
Hamaji et al. [17] believe that repeat surgical resection
alone has a limited role in the management of recurrent
type C thymoma and thymic carcinoid given the higher
rate of relapse, earlier relapses, more distant metastases,
and lower overall survival and progression-free interval.
Other contraindications include: unilateral pleural recur-
rence with extensive lesions, bilateral pleural recurrence,
early recurrence, bilateral pulmonary recurrence, cer-
vical lymph nodes metastasis, extrathoracic recurrence
and poor general condition [32].
Radiotherapy
In nonresectable local recurrences, exclusive radiotherapy
has been reported as an efficient treatment, especially on
pleural recurrences, even if irradiation had previously
been delivered. High response rates with 5-year survival
rates as high as 80 % were obtained in small retrospective
series. [53].
Chemotherapy
Many literatures suggest chemotherapy as the best choice
for nonresectable recurrent thymoma [52, 59, 60]. However,
there isn’t a well-accepted chemotherapy regiment yet.
Generally, type C thymoma has the worst sensitivity [61].
Cisplatinum combined with anthracycline is the most
popular chemotherapy regiment [62–64]. Taxol is not so
effective, but could be the drug of second-line [61].
Besides, cyclophosphamide [63], pemetrexed [65, 66],
gemcitabine combined with capecitabine [67] may also
help relieve the tumor progression.
An attractive treatment of the pleural implants of thym-
oma is hyperthermic intrapleural chemotherapy. Circula-
tion of cisplatinum (100 mg/m2) flows of 1000 to
2000 mL/min with an inflow temperature of 42 °C or
higher were required to maintain the desired temperature,
79 % of the patients have had complete local control for
periods ranging from 10 to 70 months [48]. Cisplatinum
combined with adriamycin or doxorubicin are also effect-
ive [68, 69].
Targeted therapy
In recent years, researches on the targeted therapy of re-
current thymoma have started. Epidermal Growth Factor
Receptor (EGFR) has a high expression in the cells of
thymoma, but mutations are rare, so EGFR tyrosine
kinase inhibitors may not be effective. A case report
shows that a patient with EGFR mutation fails to re-
spond to gefitinib [70]. However, some EGFR strong
positive patients achieve partial remission after treated
with cetuximab [71, 72].
Bevacizumab was tested in combination with erloti-
nib, no tumor response was observed, but stable disease
rate was 60 % [73]. 14 % patients could achieve a partial
response when treated with cixutumumab, and 76 %
have stable disease [74]. 8 % patients achieve partial re-
sponse under the treatment of histone deacetylase in-
hibitor Belinostat, and the two-year overall survival rate
is 77 % [75].
Somatostatin receptors are expressed in a variety of
malignancies including thymic epithelial tumors, so
octreotide is regarded as an alternative for recurrent
thymoma [76]. In patients whose tumor is octreotide-
reactive and treated with octreotide or octreotide
combined with prednisone, 28.5–30.3 % show disease re-
sponse, 35.7–36.8 % have stable disease [77, 78].
Multimodal treatments
As the initial operation damaged the original anatomical
structure, induced local adhesions, and recurrent thym-
oma is prone to invade main vessels and nerves, so
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secondary operation is difficult to achieve radical cure,
the rate of R0 resection is only 50–60 % [8, 12, 24]. So,
post-operative multimodal treatments are necessary for
many patients with recurrence. Several researches show
that operation followed by other treatments could
improve prognosis [17, 49, 79–81]. However, only a
small part of patients received treatment after operation
(20.4 % for chemotherapy and 20.9 % for radiotherapy)
[4]. People have not reach an agreement about the thera-
peutic regimen yet, and relevant studies are few.
Operation doesn’t achieve R0 resection is regarded as
the indication for post-operative adjuvant radiotherapy
[17]. The mostly accepted indications to adjuvant radio-
therapy are: resection performed macroscopically or
microscopically not radical, particularly in case of thym-
omas, peeled off the phrenic nerve or great vessels; in
case of any doubts about radicality of the resection, type
B2/3, because it is more aggressive; in case of biopsies
through mediastinotomy [16].
Shin et al. [82] revealed an aggressive but highly effect-
ive multimodal treatment for locally advanced, unresect-
able thymoma: induction chemotherapy (three courses
of cyclophosphamide, doxolubicin, cisplatin, and prodni-
sone), surgical resection, postoperative radiation therapy,
and consolidation chemotherapy. This multidisciplinary
approach may increase the effect of re-operation and
elevate their survival rate.
Percutaneous cryoablation is available for patients with
pleural recurrence [83]. Other studies show cortisol
alone or with tacrolimus is effective for recurrent thym-
oma [84–86].
Clinical concerns of recurrent thymoma
The recurrence is of importance to patients of thymoma.
The effect of treatment for recurrent thymoma is not as
good as primary tumor, and the prognosis is not good.
As the recurrent thymoma is relatively rare [2, 11], and
disease-free time varies, it is difficult to carry out clinical
trial. There are still some clinical concerns about recur-
rent thymoma.
It’s important and difficult to tell which patients are
likely to experience recurrence and prevent the recur-
rence. Establishing an evaluation system of the recurrent
risk is necessary. Patients of high recurrent risk may ob-
tain a benefit through neoadjuvant and adjuvant therapy,
including radiotherapy, chemotherapy and targeted ther-
apy. To those who are prone to get recurrent disease, a
more frequent than mentioned above [49] maybe mean-
ingful for early intervention.
Many doctors may concern how to achieve the early
diagnosis of recurrent thymoma. As there is tissue adhe-
sion, fibrillation and scarring induced by the resection of
primary tumor, it may be difficult to diagnose the recur-
rence by traditional imageological examination. The low
recurrent rate and lack of experience is another negative
factor. PET-CT shows an advantage in the diagnosis of
recurrent thymoma [33, 35]. Its application is limited by
the cost, however. Formulating a criteria for the diagno-
sis is of importance to recurrent thymoma.
Recurrence is an important aspect of thymoma. As
there are still concerns about the prevention, diagnosis
and management of recurrent thymoma, randomized
clinical trials of multi-center is necessary. International
collaboration should be encouraged.
The prognosis of recurrent thymoma
The 5-year and 10-year survival rates are 51–59.9 % and
42.5–43 % [2, 5]; and those of type C thymoma patients
are 30.8 and 28.2 % [2]. The 5-year survival rate follow-
ing complete resection is 64–80 % [43, 44]. Masaoka
classification, WHO histology type and complete resec-
tion are main factors affecting the prognosis [29, 44, 87].
Early recurrence (<40 months) is known as a negative
prognostic factor [15], and local recurrence, single recur-
rence both imply better prognosis [21, 32, 88]. Regarding
the patients with single-site recurrence, the 5- and 10-
year survival rates of the patients with pleural dissemin-
ation are 90.6 and 66.9 %, which indicate a trend toward
a more favorable survival compared with that observed
in the patients with recurrence at the other sites [2].
Conclusion
Recurrent thymoma is rare disease, differences between
patients are obvious. It’s difficult to evaluate the regi-
ment of multimodal treatments. Controversy about the
management of recurrent thymoma still exists. Multi-
center prospective clinical trials with large sample are





This review was not funded by any companies or groups.
Availability of data and materials
Not applicable.
Authors’ contributions
TL and HZ reviewed literature, collected data and wrote the manuscript. XZ
critically reviewed anaesthetic literature. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Luo et al. Journal of Cardiothoracic Surgery  (2016) 11:140 Page 5 of 7
Author details
1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou
310022, People’s Republic of China. 2Wenzhou Medical University, Wenzhou
325035, People’s Republic of China. 3Zhejiang Key Laboratory of Diagnosis
and Treatment Technology on Thoracic Oncology (Lung and Esophagus),
Zhejiang Cancer Hospital, Hangzhou 310022, People’s Republic of China.
Received: 23 March 2016 Accepted: 23 August 2016
References
1. Detterbeck F. International thymic malignancies interest group: a way
forward. J Thorac Oncol. 2010;5(10 Suppl 4):S365–70.
2. Mizuno T, Okumura M, Asamura H, Japanese Association for Research on
Thymus, et al. Surgical management of recurrent thymic epithelial tumors a
retrospective analysis based on the Japanese nationwide database. J Thorac
Oncol. 2015;10(1):199–205.
3. Awad WI, Symmans PJ, Dussek JE. Recurrence of stage I thymoma 32 years
after total excision. Ann Thorac Surg. 1998;66(6):2106–8.
4. Hamaji M, Ali SO, Burt BM. A meta-analysis of surgical versus nonsurgical
management of recurrent thymoma. Ann Thorac Surg. 2014;98(2):748–55.
5. Huang J, Rizk NP, Travis WD, et al. Comparison of patterns of relapse in thymic
carcinoma and thymoma. J Thorac Cardiovasc Surg. 2009;138(1):26–31.
6. Muller-Hermelink HK, Strobel P, Zettl A, et al. Combined thymic epithelial
tumors. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors.
Pathology and genetics: tumours of the lung, pleura, thymus and heart
(WHO classification of tumours). Lyon: IARC Press; 2004. p. 196–201.
7. Wright CD, Wain JC, Wong DR, et al. Predictors of recurrence in thymic
tumors: importance of invasion, World Health Organization histology, and
size. J Thorac Cardiovasc Surg. 2005;130(5):1413–21.
8. Ruffini E, Filosso PL, Oliaro A. The role of surgery in recurrent thymic tumors.
Thorac Surg Clin. 2009;19(1):121–31.
9. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after
multimodality treatment for stage III thymic tumors. Ann Thorac Surg.
2003;76(6):1866–72.
10. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77(5):1860–9.
11. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of
1,320 patients from Japan. Ann Thorac Surg. 2003;76(3):878–84.
12. Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis of
clinicopathologic features, treatment, and outcome. J Thorac Cardiovasc
Surg. 1997;113(1):55–63.
13. Pearson FG. Thoracic surgery. Philadelphia: Churchill Livingstone; 2002.
14. Ciccone AM, Rendina EA. Treatment of recurrent thymic tumors. Semin
Thorac Cardiovasc Surg. 2005;17(1):27–31.
15. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of
factors predicting survival. Ann Thorac Surg. 1995;60(4):908–13.
16. Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac
Oncol. 2010;5(10 Suppl 4):S348–51.
17. Hamaji M, Allen MS, Cassivi SD, et al. The role of surgical management in
recurrent thymic tumors. Ann Thorac Surg. 2012;94(1):247–54.
18. Safieddine N, Liu G, Cuningham K, et al. Prognostic factors for cure,
recurrence and long-term survival after surgical resection of thymoma. J
Thorac Oncol. 2014;9(7):1018–22.
19. Juel VC. Myasthenia gravis management of mysthenic ctisis and
perioperative care. Semin Neurol. 2004;24(1):75–81.
20. Bodner J, Wykypiel H, Greiner A, et al. Early experience with robot-assisted
surgery for mediastinal masses. Ann Thorac Surg. 2004;78(1):259–65.
21. Lucchi M, Basolo F, Mussi A. Surgical treatment of pleural recurrence from
thymoma. Eur J Cardiothorac Surg. 2008;33(4):707–11.
22. Ye B, Tantai JC, Ge XX, et al. Surgical techniques for early-stage thymoma:
video-assisted thoracoscopic thymectomy versus transsternal thymectomy. J
Thorac Cardiovasc Surg. 2014;147(5):1599–603.
23. Augustin F, Schmid T, Sieb M, et al. Video-assisted thoracoscopic surgery
versus robotic-assisted thoracoscopic surgery thymectomy. Ann Thorac
Surg. 2008;85(2):S768–71.
24. Regnard JF, Zinzindohoue F, Magdeleinat P, et al. Results of reresection for
recurrent thymomas. Ann Thorac Surg. 1997;64(6):1593–8.
25. Xu C, Feng QF, Fan CC, et al. Patterns and predictors of recurrence after
radical resection of thymoma. Radiother Oncol. 2015;115(1):30–4.
26. Davies SE, Macartney JC, Camplejohn RS, et al. DNA flow cytometry of
thymomas. Histopathology. 1989;15(1):77–83.
27. Buckley C, Newsom-Davis J, Willcox N, et al. Do titin and cytokine
antibodies in MG patients predict thymoma or thymoma recurrence?
Neurology. 2001;57(9):1579–82.
28. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum pro-MMP2 levels in
patients with stage IV thymoma. Surg Today. 2002;32(6):482–6.
29. Filippo L, Alfredo C, Stefano M, et al. Caveats in recurrent thymoma
management. J Thorac Oncol. 2012;7(8):1207–8.
30. Haniuda M, Kondo R, Numanami H, et al. Recurrence of thymoma
clinicopathological features, re-operation, and outcome. J Surg Oncol.
2001;78(3):183–8.
31. Margaritora S, Cesario A, Cusumano G, et al. Single-centre 40-year results of redo
operation for recurrent thymomas. Eur J Cardiothorac Surg. 2011;40(4):894–900.
32. Bae MK, Byun CS, Lee CY, et al. Clinical outcomes and prognosis of
recurrent thymoma management. J Thorac Oncol. 2012;7(8):1304–14.
33. El-Bawab HY, Abouzied MM, Rafay MA, et al. Clinical use of combined
positron emission tomography and computed tomography in thymoma
recurrence. Interact Cardiovasc Thorac Surg. 2010;11(4):395–9.
34. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal
tumors. Br J Cancer. 1996;73:882–6.
35. Ito H, Shimada K, Isogami K, et al. Recurrent thymoma radiological (CT and
FDG-PET) and histological (WHO criteria) features. Radiat Med. 2006;24(4):292–6.
36. Jung KJ, Lee KS, Han J, et al. Malignant thymic epithelial tumors:
CT—pathologic correlation. AJR Am J Roentgenol. 2001;176(2):433–9.
37. Carter BW, Benveniste MF, Truong MT, et al. State of the art: MR imaging of
thymoma. Magn Reson Imaging Clin N Am. 2015;23(2):165–77.
38. Kim SJ, Kim IJ, Kim YK. Tc-99m MIBI, Tc-99m tetrofosmin, and Tc-99m (V)
DMSA accumulation in recurrent malignant thymoma. Clin Nucl Med.
2002;27(1):30–3.
39. Kleikamp G, Schnepper U, Korfer R. Coronary artery disease and aortic valve
disease as a long-term sequel of mediastinal and thoracic irradiation. Thorac
Cardiovasc Surg. 1997;45(1):27–31.
40. Shulimzon T, Apter S, Weitzen R, et al. Radiation pneumonitis complicating
mediastinal radiotherapy postpneumonectomy. Eur Respir J. 1996;9(12):2697–9.
41. Yeoh E, Holloway RH, Russo A, et al. Effects of mediastinal irradiation on
esophageal function. Gut. 1996;38(2):166–70.
42. Singhal S, Shrager JB, Rosenthal DI, et al. Comparison of stages: thymoma-treated
complete resection with or without adjuvant radiation. Ann Thorac Surg.
2003;76(5):1635–41.
43. Quintanilla-Martinez L, Wilkins Jr EW, Choi N, et al. Thymoma. Histologic
subclassification is an independent prognostic factor. Cancer. 1994;74(2):606–17.
44. Wright CD. Management of thymomas. Crit Rev Oncol Hematol.
2008;65(2):109–20.
45. OgawaK UT, Toita T, et al. Postoperative radiotherapy for patients with
completely resected thymoma. Cancer. 2002;94:1405–13.
46. Rena O, Papalia E, Oliaro A, et al. Does adjuvant radiation therapy improve
disease-free survival in completely resected Masaoka stage II thymoma? Eur
J Cardiothorac Surg. 2007;31(1):109–13.
47. Mangi AA, Wain JC, Donahue DM, et al. Adjuvant radiation of stage III
thymoma: is it necessary? Ann Thorac Surg. 2005;79(6):1834–9.
48. Refaely Y, Simansky DA, Paley M, et al. Resection and perfusion
thermochemotherapy: a new approach for the treatment of thymic
malignancies with pleural spread. Ann Thorac Surg. 2001;72(2):366–70.
49. Bott MJ, Wang H, Travis W, et al. Management and outcomes of relapse
after treatment for thymoma and thymic carcinoma. Ann Thorac Surg.
2011;92(6):1984–91.
50. de Bree E, van Ruth S, Rutgers EJ, et al. Reoperation combined with
intraoperative hyperthermic intrathoracic perfusion chemotherapy for
pleural recurrence of thymoma. J Surg Oncol. 2002;80(4):224–5.
51. Maggi G, Casadio C, Cavallo A, et al. Thymoma: results of 241 operated
cases. Ann Thorac Surg. 1991;51(1):152–6.
52. Vita ML, Tessitore A, Cusumano G, et al. Recurrence of thymoma: re-
operation and outcome. Ann Ital Chir. 2007;78(5):375–6.
53. Urgesi A, Monetti U, Rossi G, et al. Aggressive treatment of intrathoracic
recurrences of thymoma. Radiother Oncol. 1992;24(4):221–5.
54. Sandri A, Cusumano G, Lococo F, et al. Long-term results after treatment for
recurrent thymoma a multicenter analysis. J Thorac Oncol. 2014;9(12):1796–804.
55. Okumura M, Shiono H, Inoue M, et al. Outcome of surgical treatment for
recurrent thymic epithelial tumors with reference to world health
organization histologic classification system. J Surg Oncol. 2007;95(1):40–4.
56. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a
systematic review and practice guideline. J Thorac Oncol. 2009;4(7):911–9.
Luo et al. Journal of Cardiothoracic Surgery  (2016) 11:140 Page 6 of 7
57. Dai J, Song N, Yang Y, et al. Is it valuable and safe to perform reoperation
for recurrent thymoma. Interact Cardiovasc Thorac Surg. 2015;21(4):526–31.
58. Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA
thymoma. Ann Thorac Surg. 2006;82(4):1234–9.
59. Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current
therapeutic management. J Thorac Oncol. 2009;4(1):119–26.
60. Fujii Y. Published guidelines for management of thymoma. Thorac Surg
Clin. 2011;21(1):125–9. viii.
61. Evans TL. Emerging treatment options for patients with recurrent advanced
thymic epithelial tumors. Onco Targets Ther. 2012;5:177–84.
62. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive
thymoma: a 13-year experience. Cancer. 1991;68(1):30–3.
63. Loehrer Sr PJ, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus
cyclophosphamide in metastatic or recurrent thymoma: final results of an
intergroup trial. The Eastern Cooperative Oncology Group, Southwest
Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol.
1994;12(6):1164–8.
64. Loehrer Sr PJ, Chen M, Kim K, et al. Cisplatin, doxorubicin, and
cyclophosphamide plus thoracic radiation therapy for limited-stage
nonresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15(9):3093–9.
65. Loehrer Sr PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of
pemetrexed in patients with recurrent thymoma or thymic carcinoma. J
Clin Oncol. 2006;24(18S):Abstract 7079.
66. Schmitt J, Loehrer Sr PJ. The role of chemotherapy in advanced thymoma. J
Thorac Oncol. 2010;5(10 Suppl 4):S357–60.
67. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase IIstudy of
capecitabine and gemcitabine (CAP-GEM) in patients with metastatic
pretreated thymic epithelial tumors (TETs). Ann Oncol. 2010;21(6):1168–72.
68. de Bree E, van Ruth S, Baas P, et al. Cytoreductive surgery and
intraoperative hyperthermic intrathoracic chemotherapy in patients with
malignant mesothelioma or pleural metastases of thymoma. Chest.
2002;121(2):480–7.
69. De Bree E, van Ruth S, Schotborgh CE, et al. Limited cardiotoxicity after extensive
thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy
with doxorubicin and cisplatin. Ann Surg Oncol. 2007;14(10):3019–26.
70. Nakagiri T, Funaki S, Kadota Y, et al. Does gefitinib have effects on EGFR
mutation-positive thymoma? -Case report of thymoma recurrence. Ann
Thorac Cardiovasc Surg. 2014;20(Suppl):674–6.
71. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of
metastatic and chemorefractory thymoma. Front Biosci. 2007;12:757–61.
72. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to
cetuximab. Lancet Oncol. 2007;8(5):449–50.
73. Azad A, Herbertson RA, Pook D, et al. Motesanib diphosphate (AMG706), an
oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced
thymoma. Acta Oncol. 2009;48(4):619–21.
74. Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with
recurrent or refractory advanced thymic epithelial tumours a multicentre,
open-label, phase 2 trial. Lancet Oncol. 2014;15(2):191–200.
75. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients
with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol.
2011;29(15):2052–9.
76. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor
scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the
Rotterdam experience with more than 1000 patients. Eur J Nucl Med.
1993;20(8):716–31.
77. Loehrer Sr PJ, Wang W, Johnson DH, et al. Octreotide alone or with prednisone
in patients with advanced thymoma and thymic carcinoma: an Eastern
Cooperative Oncology Group Phase II Trial. J Clin Oncol. 2004;22(2):293–9.
78. Zampa G. Targeting the therapy: octreotide in thymoma relapse. J Clin
Oncol. 2007;25(18S):Abstract 18199.
79. Spaggiari L, Casiraghi M, Guarize J. Multidisciplinary treatment ofmalignant
thymoma. Curr Opin Oncol. 2012;24(2):117–22.
80. Kunitoh H, Tamura T, Shibata T, et al. A phase II trial of dose-dense
chemotherapy, followed by surgical resection and/or thoracic radiotherapy,
in locally advanced thymoma: report of a Japan Clinical Oncology Group
trial (JCOG 9606). Br J Cancer. 2010;103(1):6–11.
81. Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy
including extended resections in stage IVA thymoma. J Thorac Cardiovasc
Surg. 2007;134(6):1477–83.
82. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to therapy
for nonresectable malignant thymoma. Ann Intern Med. 1998;129(2):100–4.
83. Abtin F, Suh RD, Nasehi L, et al. Percutaneous cryoablation for the
treatment of recurrent thymoma preliminary safety and efficacy. J Vasc
Interv Radiol. 2015;26(5):709–14.
84. Kirkove C, Berghmans J, Noel H, et al. Dramatic response of recurrent
invasive thymoma to high doses of corticosteroids. Clin Oncol (R Coll
Radiol). 1992;4(1):64–6.
85. Koshio J, Tsukada H, Nagasawa Y, et al. Successful corticosteroid therapy of
a recurrent thymoma with pure red cell aplasia. Nihon Kokyuki Gakkai
Zasshi. 2007;45(11):879–83.
86. Taguchi T, Suehiro T, Toru K, et al. Pleural dissemination of thymoma
showing tumor regression after combined corticosteroid and tacrolimus
therapy. Eur J Intern Med. 2006;17(8):575–7.
87. Verley JM, Hollmann KH. Thymoma. A comparative study of clinical stages,
histologic features, and survival in 200 cases. Cancer. 1985;55(5):1074–86.
88. Yano M, Sasaki H, Moriyama S, et al. Number of recurrent lesions is a
prognostic factor in recurrent thymoma. Interact Cardiovasc Thorac Surg.
2011;13(1):21–4.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Luo et al. Journal of Cardiothoracic Surgery  (2016) 11:140 Page 7 of 7
